Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Supportive Therapie in der Neuroonkologie
Hundsberger T. Supportive Therapie in der Neuroonkologie - Palliation bei Hirntumoren. InFo Neurologie & Psychiatrie 2016; 4:22-27.
30.07.2016Supportive Therapie in der Neuroonkologie
30.07.2016InFo Neurologie & Psychiatrie 2016; 4:22-27
Hundsberger Thomas
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Neumair P, Cerny T, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Dutly A, Warschkow R, Joos L, Jörger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
28.07.2016Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
28.07.2016Lung Cancer 2016; 100:38-44
Neumair P, Cerny Thomas, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Dutly A, Warschkow Rene, Joos L, Jörger Markus
Better survival in right-sided versus left-sided stage I - III colon cancer patients
Warschkow R, Sulz M, Marti L, Tarantino I, Schmied B, Cerny T, Gueller U. Better survival in right-sided versus left-sided stage I - III colon cancer patients. BMC cancer 2016; 16:554.
28.07.2016Better survival in right-sided versus left-sided stage I - III colon cancer patients
28.07.2016BMC cancer 2016; 16:554
Warschkow Rene, Sulz Michael, Marti Lukas, Tarantino Ignazio, Schmied Bruno, Cerny Thomas, Gueller Ulrich
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Saad F, O'Sullivan J, Federhofer J, Wirth M, Tucci M, Petrenciuc O, Nilsson S, Miller K, Lévy J, Gratt J, Heinrich D, Heidenreich A, Gillessen Sommer S, Carles J. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17:1306-16.
26.07.2016Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
26.07.2016Lancet Oncol 2016; 17:1306-16
Saad Fred, O'Sullivan Joe M, Federhofer Judith, Wirth Manfred, Tucci Marcello, Petrenciuc Oana, Nilsson Sten, Miller Kurt, Lévy Jérémy, Gratt Jeremy, Heinrich Daniel, Heidenreich Axel, Gillessen Sommer Silke, Carles Joan
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
Cathomas R, Gillessen Sommer S, Manetsch G, Bernhard J, Mohaupt M, Roggero E, Rauch D, Vilei S, Hayoz S, Kenner H, von Burg P, Elliott T, Rothermundt C, Winterhalder R, Mark M, Crabb S, Swiss Group for Clinical Cancer Research SAKK. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). Prostate 2016; 76:1519-1527.
25.07.2016Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
25.07.2016Prostate 2016; 76:1519-1527
Cathomas Richard, Gillessen Sommer Silke, Manetsch Gabriela, Bernhard Jürg, Mohaupt Markus G, Roggero Enrico, Rauch Daniel, Vilei Simona Berardi, Hayoz Stefanie, Kenner Heike, von Burg Philippe, Elliott Tony, Rothermundt Christian, Winterhalder Ralph, Mark Michael, Crabb Simon J, Swiss Group for Clinical Cancer Research SAKK
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform
Gillessen Sommer S, Gilson C, James N, Adler A, Sydes M, Clarke N. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. Eur Urol 2016; 70:906-908.
19.07.2016Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform
19.07.2016Eur Urol 2016; 70:906-908
Gillessen Sommer Silke, Gilson Clare, James Nick, Adler Amanda, Sydes Matthew R, Clarke Noel
Multiple myeloma: patient outcomes in real-world practice
Yong K, Schoen P, Raab M, Mateos M, Karlin L, Safaei R, Gonzalez-McQuire S, Flinois A, Fink L, Driessen C, Delforge M, Cavo M. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016; 175:252-264.
13.07.2016Multiple myeloma: patient outcomes in real-world practice
13.07.2016Br J Haematol 2016; 175:252-264
Yong Kwee, Schoen Paul, Raab Marc S, Mateos Maria-Victoria, Karlin Lionel, Safaei Reza, Gonzalez-McQuire Sebastian, Flinois Alain, Fink Leah, Driessen Christoph, Delforge Michel, Cavo Michele
The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Jörger M, Finn S, Cuffe S, Byrne A, Gray S. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. Expert Opin Ther Targets 2016; 20:1339-1356.
11.07.2016The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
11.07.2016Expert Opin Ther Targets 2016; 20:1339-1356
Jörger Markus, Finn Stephen P, Cuffe Sinead, Byrne Annette T, Gray Steven G
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial
Früh M, Ris H, Xyrafas A, Peters S, Mirimanoff R, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. Ann Oncol 2016; 27:1971-3.
29.06.2016Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial
29.06.2016Ann Oncol 2016; 27:1971-3
Früh Martin, Ris H B, Xyrafas A, Peters S, Mirimanoff R O, Gautschi O, Pless M, Stupp R
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program
Papazoglou D, Stenner F, Kühne R, Baumann S, Richner J, Schmid M, von Burg P, von Rohr L, Nussbaum C, Mingrone W, Barth A, Winterhalder R, Hasler L, Rothermundt C, Gillessen Sommer S, Cathomas R, Berthold D, Wannesson L, Rothschild S. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. Clin Genitourin Cancer 2016
23.06.2016Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program
23.06.2016Clin Genitourin Cancer 2016
Papazoglou Dimitrios, Stenner Frank, Kühne Reto, Baumann Sylvia, Richner Jürg, Schmid Mathias, von Burg Philippe, von Rohr Lukas, Nussbaum Catrina Uhlmann, Mingrone Walter, Barth Andreas, Winterhalder Ralph, Hasler Loretta, Rothermundt Christian, Gillessen Sommer Silke, Cathomas Richard, Berthold Dominik, Wannesson Luciano, Rothschild Sacha I
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016
20.06.2016Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
20.06.2016J Clin Oncol 2016
Colleoni Marco, Eniu Alexandru, Cagossi Katia, Rauch Daniel, Chirgwin Jacquie, Gelber Richard D, Regan Meredith M, Coates Alan S, Price Karen N, Viale Giuseppe, Kralidis Elena, Tondini Carlo, Gray Kathryn P, Gelber Shari, Láng István, Thürlimann Beat, Gianni Lorenzo, Abdi Ehtesham A, Gomez Henry L, Linderholm Barbro K, Puglisi Fabio, Goldhirsch Aron
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsky P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer 2016; 64:12-21.
17.06.2016Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
17.06.2016Eur J Cancer 2016; 64:12-21
von Minckwitz G, Jackisch C, Kümmel S, Fasching P A, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober Jens, Gerber B, Zahm D M, Hilfrich J, Costa S D, Dubsky P, Blohmer J U, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators
Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39:461-3.
15.06.2016Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
15.06.2016Oncol Res Treat 2016; 39:461-3
Reichegger Hermann, Jochum Wolfram, Förbs Diana, Hader Claudia, Früh Martin
IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.
Brown M, Glanzmann C, Huber G, Bredell M, Rordorf T, Studer G. IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80. Strahlenther Onkol 2016; 192:526-36.
15.06.2016IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.
15.06.2016Strahlenther Onkol 2016; 192:526-36
Brown Michelle L, Glanzmann Christoph, Huber Gerhard, Bredell Marius, Rordorf Tamara, Studer Gabriela
Multiple myeloma: practice patterns across Europe
Raab M, Schoen P, Mateos M, Karlin L, Safaei R, Gonzalez-McQuire S, Flinois A, Fink L, Driessen C, Delforge M, Cavo M, Yong K. Multiple myeloma: practice patterns across Europe. Br J Haematol 2016; 175:66-76.
13.06.2016Multiple myeloma: practice patterns across Europe
13.06.2016Br J Haematol 2016; 175:66-76
Raab Marc S, Schoen Paul, Mateos Maria-Victoria, Karlin Lionel, Safaei Reza, Gonzalez-McQuire Sebastian, Flinois Alain, Fink Leah, Driessen Christoph, Delforge Michel, Cavo Michele, Yong Kwee
Nerve ultrasound findings in a patient with Charcot-Marie-Tooth (CMT) Disease type 4C
Felbecker A, Leupold D, Hundsberger T (2016). Nerve ultrasound findings in a patient with Charcot-Marie-Tooth (CMT) Disease type 4C.
13.06.2016Nerve ultrasound findings in a patient with Charcot-Marie-Tooth (CMT) Disease type 4C
13.06.2016EAN
Felbecker Ansgar, Leupold Daniela, Hundsberger Thomas
Chronic inflammatory demyelinating polyneuropathy - still a challenging diagnosis
Leupold D, Schilg-Hafer L, Felbecker A, Zieglgänsberger D, Tettenborn B, Hundsberger T (2016). Chronic inflammatory demyelinating polyneuropathy - still a challenging diagnosis.
13.06.2016Chronic inflammatory demyelinating polyneuropathy - still a challenging diagnosis
13.06.2016EAN
Leupold Daniela, Schilg-Hafer Lenka, Felbecker Ansgar, Zieglgänsberger Dominik, Tettenborn Barbara, Hundsberger Thomas
Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost
Ebner F, Janni W, Bekes I, Lato K, Fink V, Wiegel T, Friedl T, Bottke D, Schramm A, De Gregorio N. Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost. Arch Gynecol Obstet 2016; 294:861-6.
02.06.2016Comparison of seroma production in breast conserving surgery with or without intraoperative radiotherapy as tumour bed boost
02.06.2016Arch Gynecol Obstet 2016; 294:861-6
Ebner Florian, Janni Wolfgang, Bekes Inga, Lato Kristian, Fink Visnja, Wiegel Thomas, Friedl Thomas Wp, Bottke Dirk, Schramm Amelie, De Gregorio Nikolaus
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Moreau P, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Zweegman S, Einsele H, van de Donk N, Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Mateos M. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs 2016; 76:989-990.
01.06.2016Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
01.06.2016Drugs 2016; 76:989-990
Moreau Philippe, Ludwig Heinz, Driessen Christoph, Palumbo Antonio, Facon Thierry, Plesner Torben, Dimopoulos Meletios, Sondergeld Pia, Sonneveld Pieter, Zweegman Sonja, Einsele Hermann, van de Donk Niels W C J, Miguel Jesus San, Lokhorst Henk, Nahi Hareth, Ben-Yehuda Dina, Cavo Michele, Cook Gordon, Delforge Michel, Mateos Maria-Victoria
Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
Warschkow R, Gueller U, Tarantino I, Cerny T, Schmied B, Thürlimann B, Jörger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016; 263:1188-98.
01.06.2016Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
01.06.2016Ann Surg 2016; 263:1188-98
Warschkow Rene, Gueller Ulrich, Tarantino Ignazio, Cerny Thomas, Schmied Bruno, Thürlimann Beat, Jörger Markus